See more : Teuza – A Fairchild Technology Venture Ltd. (TUZA.TA) Income Statement Analysis – Financial Results
Complete financial analysis of Emmaus Life Sciences, Inc. (EMMA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Emmaus Life Sciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Tarini International Limited (TARINI.BO) Income Statement Analysis – Financial Results
- RBC Bearings Incorporated (ROLL) Income Statement Analysis – Financial Results
- GigCapital5, Inc. (GIA) Income Statement Analysis – Financial Results
- Wally World Media, Inc. (WLYW) Income Statement Analysis – Financial Results
- Biomerica, Inc. (BMRA) Income Statement Analysis – Financial Results
Emmaus Life Sciences, Inc. (EMMA)
About Emmaus Life Sciences, Inc.
Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. Emmaus Life Sciences, Inc. was founded in 2000 and is headquartered in Torrance, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 29.60M | 18.39M | 20.61M | 23.17M | 22.75M | 1.32M | 128.50K | 85.10K | 100.10K | 135.10K | 130.90K | 115.00K | 745.90K | 638.50K | 700.10K | 773.50K | 238.40K | 0.00 | 0.00 | 0.00 | 6.80K | 7.89K | 8.28K | 14.26K | 20.00K |
| Cost of Revenue | 1.34M | 2.59M | 3.31M | 2.25M | 1.09M | 827.40K | 53.50K | 5.50K | 4.90K | 73.00K | 142.60K | 132.00K | 147.10K | 135.10K | 131.60K | 163.20K | 166.20K | 0.00 | 0.00 | 0.00 | 885.00 | 1.21K | 1.15K | 5.78K | 10.00K |
| Gross Profit | 28.26M | 15.80M | 17.30M | 20.92M | 21.66M | 488.10K | 75.00K | 79.60K | 95.20K | 62.10K | -11.70K | -17.00K | 598.80K | 503.40K | 568.50K | 610.30K | 72.20K | 0.00 | 0.00 | 0.00 | 5.91K | 6.68K | 7.13K | 8.48K | 10.00K |
| Gross Profit Ratio | 95.47% | 85.93% | 83.93% | 90.30% | 95.19% | 37.10% | 58.37% | 93.54% | 95.10% | 45.97% | -8.94% | -14.78% | 80.28% | 78.84% | 81.20% | 78.90% | 30.29% | 0.00% | 0.00% | 0.00% | 86.98% | 84.66% | 86.15% | 59.49% | 50.00% |
| Research & Development | 1.19M | 1.73M | 4.11M | 2.41M | 2.18M | 1.38M | 1.36M | 794.20K | 783.80K | 1.45M | 1.29M | 853.70K | 924.80K | 1.12M | 2.14M | 2.10M | 1.44M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 14.89M | 13.17M | 13.44M | 13.68M | 17.01M | 7.36M | 4.42M | 2.50M | 1.62M | 2.03M | 2.54M | 2.94M | 4.27M | 5.02M | 3.89M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 16.40K | 15.55K | 20.00K |
| Selling & Marketing | 8.64M | 7.49M | 5.88M | 4.87M | 6.98M | 1.99M | 1.40M | 550.50K | 347.90K | 390.20K | 366.30K | 997.10K | 1.23M | 870.90K | 915.80K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 23.53M | 20.66M | 19.32M | 18.54M | 23.99M | 9.36M | 5.82M | 3.05M | 1.97M | 2.42M | 2.90M | 3.94M | 5.50M | 5.89M | 4.80M | 3.99M | 1.90M | 416.21K | 28.58K | 261.09K | 144.54K | 17.06K | 16.40K | 15.55K | 20.00K |
| Other Expenses | 0.00 | -3.98M | 0.00 | 0.00 | -3.34M | 0.00 | 0.00 | 306.70K | 0.00 | 44.10K | 0.00 | 0.00 | 381.70K | 0.00 | 320.20K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -1.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 24.72M | 22.39M | 23.43M | 20.95M | 26.17M | 10.73M | 7.18M | 3.85M | 2.75M | 3.88M | 4.19M | 4.79M | 6.43M | 7.01M | 6.94M | 6.08M | 3.34M | 416.21K | 28.58K | 261.09K | 144.54K | 17.06K | 16.40K | 15.55K | 20.00K |
| Cost & Expenses | 26.06M | 24.98M | 26.74M | 23.20M | 27.26M | 11.56M | 7.23M | 3.85M | 2.76M | 3.95M | 4.33M | 4.92M | 6.58M | 7.14M | 7.07M | 6.25M | 3.51M | 416.21K | 28.58K | 261.09K | 145.43K | 18.27K | 17.55K | 21.33K | 30.00K |
| Interest Income | 681.00K | 680.00K | 761.00K | 2.30M | 232.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.38M | 0.00 | 0.00 | 99.50K | 104.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.00 | 11.00 | 0.00 |
| Interest Expense | 7.38M | 5.01M | 3.10M | 5.99M | 27.39M | 86.30K | 6.60K | 2.72M | 257.40K | 0.00 | 1.29M | 0.00 | 7.57M | 1.67M | 2.14M | 0.00 | 115.60K | 18.53K | 30.57K | 4.51K | 725.00 | 458.00 | 203.00 | 0.00 | -10.00K |
| Depreciation & Amortization | 32.00K | 53.00K | 59.00K | 60.00K | 73.00K | 113.10K | 48.70K | 7.20K | 7.60K | 10.30K | 13.00K | 18.80K | 11.90K | 9.40K | 9.10K | 6.30K | 19.90K | 225.00K | 39.33K | 0.00 | 96.00 | 0.00 | 65.00 | 231.00 | -20.00K |
| EBITDA | 3.57M | -5.50M | -12.76M | 28.00K | -26.98M | -10.13M | -7.05M | -3.19M | -3.12M | -2.63M | -4.19M | -4.79M | -1.29M | -7.80M | -6.67M | -5.47M | -3.25M | 553.80K | -1.09M | -261.09K | -138.63K | -10.38K | -9.20K | -6.84K | -30.00K |
| EBITDA Ratio | 12.07% | -35.81% | -39.02% | 0.07% | -36.01% | -769.82% | -5,490.19% | -4,726.56% | -2,179.42% | -3,654.92% | 875.63% | -4,162.70% | -779.93% | -812.51% | -850.25% | -706.89% | -1,407.97% | 0.00% | 0.00% | 0.00% | -2,041.27% | -131.43% | -111.20% | -47.98% | -150.00% |
| Operating Income | 3.54M | -6.59M | -6.13M | -43.00K | -4.51M | -10.24M | -7.10M | -3.77M | -2.66M | -3.82M | -4.20M | -4.81M | -5.83M | -6.51M | -6.69M | -5.47M | -3.27M | -416.21K | -28.58K | -261.09K | -138.63K | -10.38K | -9.27K | -7.07K | -10.00K |
| Operating Income Ratio | 11.96% | -35.81% | -29.73% | -0.19% | -19.83% | -778.78% | -5,528.09% | -4,426.32% | -2,653.75% | -2,825.17% | -3,209.01% | -4,179.04% | -781.53% | -1,018.79% | -955.88% | -707.71% | -1,371.48% | 0.00% | 0.00% | 0.00% | -2,039.86% | -131.43% | -111.99% | -49.60% | -50.00% |
| Total Other Income/Expenses | -7.33M | -3.98M | -9.79M | 1.01M | -50.17M | -317.80K | -6.60K | -2.17M | -724.60K | 1.16M | -6.69M | 1.89M | -2.50M | -1.67M | -1.82M | 104.00K | -8.70K | -18.53K | 8.76K | -4.51K | -629.00 | -458.00 | -197.00 | 11.00 | -10.00K |
| Income Before Tax | -3.79M | -10.63M | -15.92M | 719.00K | -54.68M | -10.33M | -7.11M | -5.94M | -3.38M | -2.65M | -10.89M | -2.91M | -8.87M | -8.17M | -8.52M | -5.37M | -3.28M | -434.74K | -19.82K | -265.60K | -139.26K | -10.83K | -9.47K | -7.06K | -20.00K |
| Income Before Tax Ratio | -12.81% | -57.78% | -77.25% | 3.10% | -240.32% | -785.34% | -5,533.23% | -6,978.73% | -3,377.62% | -1,965.14% | -8,317.19% | -2,534.26% | -1,188.54% | -1,280.06% | -1,216.25% | -694.26% | -1,375.13% | 0.00% | 0.00% | 0.00% | -2,049.12% | -137.23% | -114.37% | -49.53% | -100.00% |
| Income Tax Expense | -59.00K | 60.00K | 25.00K | -381.00K | 164.00K | 1.90K | 2.60K | 2.00K | 5.00K | 5.20K | 800.00 | 1.90K | 1.30K | 800.00 | 7.20K | 1.40K | 800.00 | 800.00 | 800.00 | 800.00 | 800.00 | 800.00 | 800.00 | 800.00 | 20.00K |
| Net Income | -3.73M | -10.69M | -15.95M | 1.35M | -54.84M | -9.60M | -7.11M | -5.94M | -3.38M | -2.66M | -10.91M | -3.41M | -8.87M | -8.17M | -8.52M | -5.37M | -3.28M | -435.54K | -20.62K | -266.40K | -140.06K | -11.63K | -10.27K | -7.86K | -40.00K |
| Net Income Ratio | -12.61% | -58.10% | -77.37% | 5.84% | -241.04% | -729.66% | -5,535.25% | -6,981.08% | -3,376.02% | -1,970.98% | -8,332.62% | -2,962.43% | -1,188.71% | -1,280.19% | -1,217.28% | -694.44% | -1,375.46% | 0.00% | 0.00% | 0.00% | -2,060.89% | -147.37% | -124.03% | -55.14% | -200.00% |
| EPS | -0.07 | -0.22 | -0.32 | 0.03 | -1.30 | -11.08 | -15.15 | -55.54 | -39.83 | -32.17 | -172.68 | -2.14K | -5.69K | -5.63K | -7.35K | -7.65K | -2.11K | -279.91 | -13.25 | -171.21 | -90.01 | -7.48 | -6.60 | -5.05 | 0.00 |
| EPS Diluted | -0.07 | -0.22 | -0.32 | 0.03 | -1.30 | -11.08 | -15.15 | -55.54 | -39.83 | -32.17 | -172.68 | -2.14K | -5.69K | -5.63K | -7.35K | -7.65K | -2.11K | -279.91 | -13.25 | -171.21 | -90.01 | -7.48 | -6.60 | -5.05 | 0.00 |
| Weighted Avg Shares Out | 53.11M | 49.44M | 49.25M | 48.90M | 42.26M | 866.59K | 469.57K | 106.97K | 84.84K | 82.77K | 63.17K | 1.60K | 1.56K | 1.45K | 1.16K | 702.00 | 1.56K | 1.56K | 1.56K | 1.56K | 1.56K | 1.56K | 1.56K | 1.56K | 49.31M |
| Weighted Avg Shares Out (Dil) | 53.11M | 49.44M | 49.25M | 48.90M | 42.26M | 866.60K | 469.57K | 106.97K | 84.84K | 82.77K | 63.17K | 1.60K | 1.56K | 1.45K | 1.16K | 702.00 | 1.56K | 1.56K | 1.56K | 1.56K | 1.56K | 1.56K | 1.56K | 1.56K | 49.31M |
Emmaus Life Sciences says its Endari sickle cell treatment to be added to Florida Medicaid's preferred drug list
Emmaus Life Sciences Inc (OTCQX:EMMA) has said the Florida Medicaid Pharmaceutical & Therapeutics Committee has approved adding Endari, the company's prescription-grade L-glutamine oral powder for the treatment of sickle cell disease, to the Florida Medicaid Preferred Drug List (PDL) with...
Emmaus Life Sciences wins marketing authorization for Endari in United Arab Emirates
Emmaus Life Sciences Inc (OTCQX:EMMA) has announced the approval of its application for marketing authorization of its Endari sickle cell treatment from the United Arab Emirates (UAE) Ministry of Health after a five-month review. During the review period, Endari was...
Emmaus Life Sciences is tackling debilitating sickle cell disease as it eyes other remedies
“Our goal was not to develop a pharmaceutical company but just to come up with something practical and safe and effective,” explains Dr Yutaka Niihara, as he talks about how he and colleague Willis Lee formed Emmaus Life Sciences Inc...
Emmaus Life Sciences to Present at the H.C. Wainwright BioConnect Conference
TORRANCE, Calif., Jan. 4, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced that Yutaka Niihara, M.D.
Emmaus Life Sciences releases new post-hoc analysis of Phase 3 study data highlighting effectiveness of Endari in treating sickle cell disease
Emmaus Life Sciences Inc (OTCQX:EMMA) announced positive transfusion data from a post-hoc analysis of its Phase 3 study of Endari in patients with sickle cell disease. Endari is a prescription L-glutamine oral powder that is approved by the US Food...
Emmaus Life Sciences to Webcast Live at Life Sciences Investor Forum on December 16th
TORRANCE, Calif., Dec. 9, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced that Yutaka Niihara, M.D.
Emmaus Life Sciences posts $5.8M in 3Q revenue as efforts to expand access to Endari sickle cell disease treatment bear fruit
Emmaus Life Sciences Inc (OTCQX:EMMA) reported its 3Q financial results that showed the company generated revenue of $5.8 million, up 3% from the $5.6 million it posted during the same period last year. The results showed the company is progressing...
Emmaus Life Sciences announces partnership with UpScript to provide telehealth solutions to sickle cell disease patients
Emmaus Life Sciences Inc (OTCQX:EMMA) said it has partnered with UpScript IP Holdings LLC, to offer telehealth solutions to sickle cell disease patients, expanding access to Endari, Emmaus' prescription L-glutamine oral powder for the treatment of the disease. The Torrance,...
Emmaus Life Sciences signs agreement with Asembia to expand support services and access to prescription medicine for sickle cell disease
Emmaus Life Sciences Inc (OTCQX:EMMA) announced that it has entered into an agreement with Asembia to provide expanded support services and simplify access to Endari — the company's prescription L-glutamine oral powder for the treatment of sickle cell disease. The...
Emmaus Life Sciences Acquires Key Intellectual Property Rights to Novel IRAK4 Inhibitor From Kainos Medicine
TORRANCE, Calif., Oct. 12, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced the signing of an agreement with Kainos Medicine, Inc. (Kainos), granting Emmaus an exclusive...
Source: https://incomestatements.info
Category: Stock Reports